I agree, but I think FDA Approval sends this much higher than $5.00-$7.00. This just needs much more awareness. Chart is ALMOST primed for a nice little breakout again, just need to cross $2.25 and then $2.53 and I think we can pop again.
Yesterday's news should have run this to $3.00-$3.50. Approaching other cancers besides just prostate, is absolutely huge for the company. Our only problem is that nobody follows this stock.
Perhaps we get a delayed response from the news yesterday and run today.